Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
07 2023
Historique:
received: 02 12 2022
accepted: 29 03 2023
pmc-release: 01 07 2024
medline: 20 6 2023
pubmed: 10 4 2023
entrez: 9 4 2023
Statut: ppublish

Résumé

Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with SSRI-like properties (i.e., vilazodone and vortioxetine) are primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6, CYP2C19, and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability. In addition, the pharmacodynamic genes SLC6A4 (serotonin transporter) and HTR2A (serotonin-2A receptor) have been examined in relation to efficacy and side effect profiles of these drugs. This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability. We provide recommendations for using CYP2D6, CYP2C19, and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A, which do not support their clinical use in antidepressant prescribing.

Identifiants

pubmed: 37032427
doi: 10.1002/cpt.2903
pmc: PMC10564324
mid: NIHMS1920157
doi:

Substances chimiques

Selective Serotonin Reuptake Inhibitors 0
Cytochrome P-450 CYP2D6 EC 1.14.14.1
Cytochrome P-450 CYP2B6 EC 1.14.14.1
Cytochrome P-450 CYP2C19 EC 1.14.14.1
Serotonin Plasma Membrane Transport Proteins 0
Serotonin 333DO1RDJY
Antidepressive Agents 0
Citalopram 0DHU5B8D6V
CYP2B6 protein, human EC 1.14.14.1
CYP2C19 protein, human EC 1.14.14.1
SLC6A4 protein, human 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-68

Subventions

Organisme : NIGMS NIH HHS
ID : R24 GM115264
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010135
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD099775
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010615
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM123930
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001425
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD098757
Pays : United States

Informations de copyright

© 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.

Références

Basic Clin Pharmacol Toxicol. 2014 Dec;115(6):552-9
pubmed: 24766668
Pharmacogenomics. 2019 Jan;20(1):37-47
pubmed: 30520364
J Clin Psychopharmacol. 2016 Oct;36(5):483-91
pubmed: 27518478
Biol Psychiatry. 2013 Mar 15;73(6):546-54
pubmed: 23158458
Clin Transl Sci. 2022 Oct;15(10):2514-2527
pubmed: 35997001
J Psychopharmacol. 2012 Mar;26(3):398-407
pubmed: 21926427
Clin Pharmacol Ther. 2021 Feb;109(2):352-366
pubmed: 32602114
Ther Drug Monit. 2008 Aug;30(4):474-82
pubmed: 18641553
Clin Pharmacol Ther. 2021 Jul;110(1):82-97
pubmed: 33448339
Clin Pharmacol Ther. 2022 Dec;112(6):1303-1317
pubmed: 36111494
Pharmacogenomics J. 2018 Sep;18(5):613-622
pubmed: 29795409
Pharmacopsychiatry. 2011 Sep;44(6):195-235
pubmed: 21969060
Psychopharmacology (Berl). 2017 Oct;234(20):3075-3081
pubmed: 28770276
J Clin Med. 2020 Sep 07;9(9):
pubmed: 32906709
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Biochem Pharmacol. 2009 Jul 15;78(2):184-90
pubmed: 19464434
Pharmacotherapy. 2002 Aug;22(8):1001-6
pubmed: 12173784
Ther Drug Monit. 2003 Dec;25(6):738-42
pubmed: 14639062
Front Psychiatry. 2022 Mar 29;13:867840
pubmed: 35422716
Clin Transl Sci. 2022 Feb;15(2):371-383
pubmed: 34562070
J Affect Disord. 2020 Aug 1;273:254-264
pubmed: 32421611
Clin Pharmacol Ther. 2019 May;105(5):1256-1262
pubmed: 30506572
J Clin Psychopharmacol. 2006 Apr;26(2):211-2
pubmed: 16633156
Exp Clin Psychopharmacol. 2020 Oct;28(5):589-600
pubmed: 31750687
J Am Acad Child Adolesc Psychiatry. 2020 Nov;59(11):1240-1251
pubmed: 31682918
Clin Pharmacol Ther. 2022 Dec;112(6):1318-1328
pubmed: 36149409
Mol Neurobiol. 2017 Dec;54(10):8386-8403
pubmed: 27933583
Eur J Clin Pharmacol. 2008 Dec;64(12):1181-8
pubmed: 18677622
Lancet Psychiatry. 2016 Jun;3(6):585-90
pubmed: 27133546
J Neurosci Res. 2002 Mar 15;67(6):812-22
pubmed: 11891796
Clin Transl Sci. 2020 Jan;13(1):116-124
pubmed: 31647186
Clin Pharmacol Ther. 2015 Aug;98(2):127-34
pubmed: 25974703
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:183-94
pubmed: 23733030
Mol Psychiatry. 2013 Mar;18(3):273-87
pubmed: 22565785
Ann Pharmacother. 2013 Oct;47(10):1330-41
pubmed: 24259697
Basic Clin Pharmacol Toxicol. 2019 Feb;124(2):170-180
pubmed: 30192434
J Am Acad Child Adolesc Psychiatry. 2018 Apr;57(4):235-244.e2
pubmed: 29588049
Clin Pharmacol Ther. 2007 Apr;81(4):510-6
pubmed: 17301735
Behav Genet. 2015 Mar;45(2):255-61
pubmed: 25564228
Clin Transl Sci. 2022 Sep;15(9):2135-2145
pubmed: 35668575
Mol Neurobiol. 2016 Oct;53(8):5510-26
pubmed: 26464328
Clin Pharmacol Ther. 2020 Jan;107(1):154-170
pubmed: 31544239
J Pers Med. 2021 Dec 09;11(12):
pubmed: 34945806
Drug Metab Dispos. 2003 Mar;31(3):289-93
pubmed: 12584155
JAMA Psychiatry. 2014 Sep;71(9):1006-14
pubmed: 25006837
Neuropharmacology. 1992 Oct;31(10):997-1000
pubmed: 1279447
Crit Care Nurse. 2017 Feb;37(1):49-54
pubmed: 28148614

Auteurs

Chad A Bousman (CA)

Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada.
Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.

James M Stevenson (JM)

Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Laura B Ramsey (LB)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Katrin Sangkuhl (K)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

J Kevin Hicks (JK)

Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida, USA.

Jeffrey R Strawn (JR)

Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA.
Division of Child & Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Ajeet B Singh (AB)

School of Medicine, IMPACT Institute, Deakin University, Burwood, Victoria, Australia.

Gualberto Ruaño (G)

Institute of Living at Hartford Hospital, Hartford, Connecticut, USA.
Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Daniel J Mueller (DJ)

Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

Evangelia Eirini Tsermpini (EE)

Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Jacob T Brown (JT)

Department of Pharmacy Practice & Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota, USA.

Gillian C Bell (GC)

Genome Medical, South San Francisco, California, USA.

J Steven Leeder (JS)

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Andrea Gaedigk (A)

Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute, Kansas City, Missouri, USA.
School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Stuart A Scott (SA)

Department of Pathology, Stanford University, Palo Alto, California, USA.
Stanford Medicine Clinical Genomics Program, Stanford Medicine, Stanford, California, USA.

Teri E Klein (TE)

Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

Kelly E Caudle (KE)

Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Jeffrey R Bishop (JR)

Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH